ELEVATED lipoprotein(a) was associated with more than twice the hazard of recurrent myocardial infarction in patients with Type 2 diabetes following acute coronary syndrome or percutaneous coronary intervention, according to a systematic review and meta-analysis involving 7,887 patients.
The findings highlighted the potential contribution of lipoprotein(a) to residual cardiovascular risk despite secondary prevention, although its association with repeat coronary revascularisation remained uncertain.
Researchers conducted a systematic review and meta-analysis to investigate whether elevated lipoprotein(a) concentrations were associated with recurrent myocardial infarction and repeat coronary revascularisation in patients with diabetes.
The analysis focused on patients who had previously experienced acute coronary syndrome (ACS) or undergone percutaneous coronary intervention (PCI), a population at increased risk of subsequent ischaemic events.
Following a systematic search of three electronic databases, seven observational studies involving 7,887 patients were included.
Eligible studies reported hazard ratios for recurrent cardiovascular outcomes, which researchers pooled using random-effects models.
The primary objective was to clarify whether lipoprotein(a), a contributor to residual cardiovascular risk, could provide additional prognostic information in this high-risk population.
Patients with elevated lipoprotein(a) demonstrated a significantly increased hazard of recurrent myocardial infarction (MI) compared with those without elevated concentrations (pooled hazard ratio: 2.17; 95% CI: 1.02–4.62).
However, substantial between-study heterogeneity was identified (I²=75%), indicating considerable variability in the reported associations.
For repeat coronary revascularisation, elevated lipoprotein(a) was associated with a numerically higher hazard, but the finding was not statistically significant (pooled hazard ratio: 1.68; 95% CI: 0.79–3.57).
Heterogeneity was also substantial for this outcome (I²=78%).
These results suggested that elevated lipoprotein(a) was associated with recurrent myocardial infarction, while evidence for its relationship with subsequent coronary revascularisation remained inconclusive.
The findings highlighted lipoprotein(a) as a potential marker of residual cardiovascular risk among patients with diabetes following ACS or PCI.
However, researchers emphasised several limitations, including the observational nature of the included studies, substantial heterogeneity, and limited evidence concerning repeat revascularisation.
Consequently, the associations could not establish a causal relationship between elevated lipoprotein(a) and recurrent cardiovascular events.
Overall, the analysis supported further investigation of lipoprotein(a) measurement as a potential component of cardiovascular risk stratification following ACS.
Additional research is needed to clarify its prognostic value and determine how these findings might inform secondary prevention strategies in patients with Type 2 diabetes.
Reference
Echeverria-Ortegon E et al. Elevated Lipoprotein(a) Predicts Recurrent Myocardial Infarction in Diabetic Patients Following Acute Coronary Syndromes. Clinical Cardi. 2026.
Image credit: on Adobestock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
